Journal article

Low Prevalence of Nirmatrelvir-Ritonavir Resistance-Associated Mutations in SARS-CoV-2 Lineages From Botswana.

Authors/Editors

Research Areas

Currently no objects available


Publication Details

Author list: Choga, Bareng, Moraka, Maruapula, Gobe, Ndlovu, Zuze, Motshosi, Seru, Matsuru, Boitswarelo, Matshaba, Gaolathe, Mosepele, Makhema, Tamura, Li, Shapiro, Lockman, Gaseitsiwe, Moyo

Publication year: 2024

Journal name in source: Open forum infectious diseases

Volume number: 11

Issue number: 7

ISSN: 2328-8957



BACKGROUND\nMETHODS\nRESULTS\nCONCLUSIONS\nWe evaluated naturally occurring nirmatrelvir-ritonavir (NTV/r) resistance-associated mutations (RAMs) among severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains from Botswana, a country with no NTV/r use to date, in order to recommend the usage of the agent for high-risk patients with coronavirus disease 2019 (COVID-19).\nWe conducted a retrospective analysis using 5254 complete SARS-CoV-2 sequences from Botswana (September 2020-September 2023). We evaluated the mutational landscape of SARS-CoV-2 3-Chymotrypsin-like protease (3CLpro) relative to the highlighted list of RAMs granted Food and Drug Administration Emergency Use Authorization in 2023.\n < .001) in Delta (24/35) compared with Beta (4/34) and Omicron (6/34) sequences.\nThe frequency of NTV/r RAMs in Botswana was low. Higher rates were observed in Delta VOCs compared to Omicron and Beta VOCs. As NTV/r use expands globally, continuous surveillance for drug-resistant variants is essential, given the RAMs identified in our study.


Projects

Currently no objects available


Keywords

Currently no objects available


Documents

Currently no objects available


Last updated on 2025-27-11 at 14:21